Compare ADMA Biologics Inc (ADMA) vs Freeport-McMoRan Inc (FCX) Price & Performance

ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.

The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.

FCX trades at $59.27, down 2.77% on the day, with a bearish technical signal but strong fundamentals including a 10.34% net income margin and consistent earnings beats. Recent news highlights copper demand growth from AI and energy transitions, positioning FCX as a key player. Cash flow trends show improving operational performance, though net cash flow remains negative due to heavy investments.

Outlook is positive with a consensus price target of $71.81, implying 21% upside, supported by robust copper demand and expansion projects. Risks include commodity price volatility and execution challenges. Analyst sentiment is bullish with 59% buy ratings, but investors should monitor debt levels and global economic conditions.